chartexchange

IBRX261120P00012000
IBRX Nov 20 2026 12.00 Put
optionOPRA

InactiveOct 9, 2026
2.20USD-26.667%(-0.80)20Vol74OI
Loading…
Underlying
Underlying Price
$8.48
Type
Put
Strike
12
Expiration
Nov 20, 2026
DTE
31d
Moneyness
ITM
Intrinsic
$3.52
IBRX 12 Put Across Expirations
ExpirationDTELastChangeVolOpen Int
Oct 23, 20263d——00
Oct 30, 202610d——00
Nov 6, 202617d——00
Nov 13, 202624d$2.47+0.00%11
Nov 20, 202631d$2.20-26.67%2074
Nov 27, 202638d——00
Dec 18, 202659d——00
Jan 15, 202787d$3.30-10.81%4881
Mar 19, 2027150d$4.10+2.24%343
Apr 16, 2027178d$4.00-15.79%13
May 21, 2027213d$4.80-20.00%16
Aug 20, 2027304d——00
Nov 19, 2027395d——00
Jan 21, 2028458d$4.98-4.23%1042
Mar 17, 2028514d——00
Jan 19, 2029822d$6.00-3.54%22
IBRX Nearby Strikes · Nov 20, 2026
StrikeLastChangeVolOpen IntMoneyness
6 P$0.10-23.08%2502,963OTM
7 P$0.25+66.67%1,0673,286OTM
8 P$0.55+30.95%2641,909OTM
9 P$0.90+21.62%651,550ITM
10 P$1.48+28.70%99735ITM
11 P$2.20+41.03%7394ITM
12 P$2.20-26.67%2074ITM
13 P$3.60+16.88%23ITM
14 P——00ITM
15 P——00ITM
16 P——00ITM
17 P——00ITM
18 P——00ITM
IBRX Profile

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.